% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Wolf:277751,
      author       = {R. J. Wolf and V. Winkler and M. Mattke and M. Uhl and J.
                      Debus$^*$},
      title        = {{I}ntensity-modulated radiotherapy for the management of
                      primary and recurrent chordomas: a retrospective long-term
                      follow-up study.},
      journal      = {Reports of practical oncology and radiotherapy},
      volume       = {28},
      number       = {2},
      issn         = {1507-1367},
      address      = {Poznań},
      publisher    = {Great Poland Cancer Centre},
      reportid     = {DKFZ-2023-01468},
      pages        = {207 - 216},
      year         = {2023},
      note         = {#LA:E050#},
      abstract     = {Chordomas have a high risk of recurrence. Radiotherapy (RT)
                      is required as adjuvant therapy after resection. Sufficient
                      radiation doses for local control (LC) can be achieved using
                      either particle therapy, if this technology is available and
                      feasible, or intensity-modulated radiotherapy.57 patients
                      (age, 11.8-81.6 years) with chordomas of the skull base,
                      spine and pelvis who received photon radiotherapy between
                      1995 and 2017 were enrolled in the study. Patients were
                      treated at the time of initial diagnosis $(68.4\%)$ or
                      during recurrence $(31.6\%).$ 44 patients received adjuvant
                      radiotherapy and 13 received definitive radiotherapy. The
                      median total dose to the physical target volume was 70 Gy
                      equivalent dose in 2 Gy fractions (EQD2) (range: 54.7-82.5)
                      in 22-36 fractions.LC was $76.4\%,$ $58.4\%,$ $46.7\%$ and
                      $39.9\%$ and overall survival (OS) was $98.3\%,$ $89\%,$
                      $76.9\%$ and $47.9\%$ after 1, 3, 5 and 10 years,
                      respectively, with a median follow-up period of 6.5 years
                      (range, 0.5-24.3 years). Age, dose and treatment concept
                      (post-operative or definitive) were significant prognostic
                      factors for OS. Primary treatment, macroscopic tumour at RT
                      and size of the irradiated volume were statistically
                      significant prognostic factors for LC.Photon treatment is a
                      safe and effective treatment for chordomas if no particle
                      therapy is available. The best results can be achieved
                      against primary tumours if the application of curative doses
                      is possible due to organs at risk in direct proximity. We
                      recommend high-dose radiotherapy, regardless of the
                      resection status, as part of the initial treatment of
                      chordoma, using the high conformal radiation technique if
                      particle therapy is not feasible.},
      keywords     = {chordoma (Other) / long-term follow-up (Other) / photon
                      (Other) / radiotherapy (Other)},
      cin          = {E050},
      ddc          = {610},
      cid          = {I:(DE-He78)E050-20160331},
      pnm          = {315 - Bildgebung und Radioonkologie (POF4-315)},
      pid          = {G:(DE-HGF)POF4-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37456699},
      pmc          = {pmc:PMC10348326},
      doi          = {10.5603/RPOR.a2023.0022},
      url          = {https://inrepo02.dkfz.de/record/277751},
}